Diagnosis and management of angioedema

Česká verzia

Authors: Gavorník P. ¹; Dukát A. ^1,2; Gašpar Ľ. ^1,3; Gubo G. ^1,4; Bežillová N. ^1,5; Kováčová M. ⁶; Gavorníková E. ^1,7; Petrášová A. ⁸; Gašparová I. ^1,9; Sabolová L. ^10,11; Kučera M. ^3,12; Kusendová K. ¹³; Uhrinová A. ^1,14; Bendžala M. ^1,15; Mesárošová D. ^3,11; Fialová V. ¹
Authors place of work: Angiologická sekcia Slovenskej lekárskej komory, Slovenská republika 2 V. interná klinika LF UK a UN Bratislava, Slovenská republika 3 I. interná klinika LF UK a UN Bratislava, Slovenská republika 4 Homerton University Hospital Foundation Trust, Homerton ¹
Published in the journal: Kardiol Rev Int Med 2018, 20(4): 286-293

Summary

Angioedema is defined as a vascular reaction of the deep dermis and/or subcutaneous/submucosal tissues with localised vasodilatation and increased permeability of blood vessels resulting in tissue swelling. Angioedema can be mediated by bradykinin or mast cell mediators, including histamine. Bradykinin-mediated angioedema can occur either on a hereditary (HAE) or acquired (AAE) basis, with or without a deficiency/defect of C1 inhibitor (C1-INH). Three forms of HAE have been defined: HAE due to C1-INH deficiency (type 1 HAE, HAE-1), characterised by low antigenic and functional C1-INH levels; HAE due to C1-INH dysfunction (type 2 HAE, HAE-2), characterised by normal (or elevated) antigenic but low functional C1-INH levels; and HAE with normal C1-INH antigenic and functional levels (HAE-3). Acquired C1-INH deficiency refers to patients with angioedema due to C1-INH deficiency on an acquired basis. There are several types of acquired angioedema not due to C1-INH deficiency, which can be bradykinin-mediated (e.g., angiotensin-converting enzyme inhibitor-induced angioedema) or mast-cell-mediator-histamine-mediated (e.g., anaphylactic angioedema and urticarial angioedema). In recent years there have been several changes in how we look at anaphylaxis. The spectrum of trigger factors and diagnostic and therapeutic algorithms has changed significantly. Anaphylaxis is defined as any sudden severe hypersensitive reaction which can potentially lead to death.

Key words:

angioedema – angiology/ vascular medicine – AS SMC’ guidelines – CEAP – clinical-etiology-anatomy-patophysiology diagnosis – prevention – therapy

Zdroje

1. Craig T, Pürsün E, Bork K et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5(12): 182– 199. doi: 10.1097/ WOX.0b013e318279affa.

2. Sánchez-Borges M, Asero R, Ansodegui IJ et al. WAO Scientific and Clinical Issues Council. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012; 5(11): 125– 147. doi: 10.1097/ WOX.0b013e3182758d6c.

3. Thong B, Mirakian R, Castells M et al. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/ hypersensitivity. World Allergy Organ J 2011; 4(12): 257– 270. doi: 10.1097/ WOX.0b013e31823dc02c.

4. Valent P, Klion AD, Rosenwasser LJ et al. International Consensus on: Eosinophil Disorders. World Allergy Organ J 2012; 5(12): 174– 181. doi: 10.1097/ WOX.0b013e31827f4192.

5. Jeseňák M, Bánovčin P. Hereditárny angioedém na Slovensku – stále veľká neznáma? Pediatria pre prax 2013; 14 (Suppl 1): 10– 12.

6. Gavorník P. Etiopatogenéza a diferenciálna diagnóza edémových stavov. Kardiológia/ Cardiology 2009; 18(2): 73– 78.

7. Sampson HA, Munoz-Furlong A, Campbell RL et al. Second symposium on the definition management of anaphylaxis: summary report – Second National Institute of and Infectious Disease/ Food Allergy Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117(2): 391– 397. doi: 10.1016/ j.jaci.2005.12.1303.

8. Kadaňka Z, Peška S, Bednařík J. Orolinguální angioedém jako komplikace trombolytické léčby pacientů s akutní ischemickou cévní mozkovou příhodou. Neurológia pre prax 2013; 14(1): 50– 52.

9. Simons FE, Ardusso LR, M Beatrice Bilò MB et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4(2): 13– 37. doi: 10.1097/ WOX.0b013e318211496c.

10. Boyce JA, Assa’ad A, Burks AW et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126 (6 Suppl): S1– S58. doi: 10.1016/ j.jaci.2010.10.007.

11. Zanichelli A. Medical management of hereditary angioedema: review for the internist. Gazz Med Ital 2013; 172(3): 185–199.

12. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/ GA(2)LEN/ EDF/ WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64(10): 1417– 1426. doi: 10.1111/ j.1398-9995.2009.02178.x.

13. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/ Ga(2)LEN/ EDF/ WAO guideline: management of urticaria. Allergy 2009; 64(10): 1427– 1443. doi: 10.1111/ j.1398-9995.2009.02178.x.

14. Adam Z, Tomiška M, Krejčí M et al. Diferenciální diagnostika eozinofilie. Vnitř Lék 2009; 55 (Suppl 1): 125– 144.

15. Kestler A, Keyes L. Uvular Angioedema (Quincke's Disease). N Engl J Med 2003; 349(9): 867– 858. doi: 10.1056/ NEJMicm020617.

16. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359(10): 1027– 1036. doi: 10.1056/ NEJMcp0803977.

17. Králičková P, Burešová E, Freiberger T et al. Hereditární angioedém – opomíjená diagnoza. Vnitř Lék 2010; 56(9): 927– 931.

18. Zuraw BL, Busse PJ, White M et al. nanofiltered c1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363(6): 513– 522. doi: 10.1056/ NEJMoa0805538.

19. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363(6): 532– 541. doi: 10.1056/ NEJMoa0906393.

20. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363(6): 523– 531. doi: 10.1056/ NEJMoa0905079.

21. Maurer M, Rosén K, Hsieh HJ et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368(10): 924– 935. Correction: N Engl J Med 2013; 368(24): 2340– 2341. doi: 10.1056/ NEJMoa1215372.

22. Szturz P, Adam Z, Klabusay M et al. Schnitzler syndrom: popis případu, zkušenosti s léčbou glukokortikoidy a preparátem anakinra (KineretTM) a sledování cytokinové odpovědi organizmu. Vnitř Lék 2011; 57(1): 97– 112.

23. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379(9814): 474– 341. doi: 10.1016/ S0140-6736(11)60935-5.

24. Decker WW, Campbell RL, Manivannan V et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008; 122(6): 1161– 1165. doi: 10.1016/ j.jaci.2008.09.043.

25. Lin RY, Anderson AS, Shah SN et al. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990– 2006. Ann Allergy Asthma Immunol 2008; 101(4): 387– 393. doi: 10.1016/ S1081-1206(10)60315-8.

26. Helbing A, Hurmi T, Mueller UR et al. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940.000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004; 34(2): 285– 290.

27. Benkelfat R, Gouin S, Larose G et al. Medication errors in the management of anaphylaxis in a pediatric emergency department. J Emerg Med 2013; 45(3): 419– 425. doi: 10.1016/ j.jemermed.2012.11.069.

28. Nowak R, Farrar JR, Brenner JR et al. Customizing anaphylaxis guidelines for emergency medicine. J Emerg Med 2013; 45(2): 299– 306. doi: 10.1016/ j.jemermed.2013.01.018.

29. Goldflam K, Silvers CT. Exercise-induced anaphylaxis as a cause of syncope. J Emerg Med 2012; 43(4): 651– 654. doi: 10.1016/ j.jemermed.2010.05.070.

30. Moellman JJ, Bernstein JA. Diagnosis and management of hereditary angioedema: an emergency medicine perspective. J Emerg Med 2012; 43(2): 391– 400. doi: 10.1016/ j.jemermed.2011.06.125.

31. Hassen GW, Kalantari H, Parraga M et al. Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor-induced angioedema. J Emerg Med 2013; 44(4): 764– 772. doi: 10.1016/ j.jemermed.2012.07.055.

32. Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med 2010; 153(2): 90– 98. doi: 10.7326/ 0003-4819-153-2-201007200-00005.

33. Winters ME, Rosenbaum S, Vilke GM et al. Emergency department management of patients with ace-inhibitor angioedema. J Emerg Med 2013; 45(5): 775– 780. doi: 10.1016/ j.jemermed.2013.05.052.

34. Lewis LM. Angioedema: etiology, pathophysiology, current and emerging therapies. J Emerg Med 2013; 45(5): 789– 796. doi: 10.1016/ j.jemermed.2013.03.045.

35. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. 2. vyd. Bratislava: Univerzita Komenského-Vydavateľstvo UK 2001: 268.

36. Gavorník P. Angiológia1 pre všeobecných praktických lekárov. Flebológia. 1. vyd. Bratislava: Dr. Josef Raabe 2013: 125.

37. Nolan JP, Hazinski MF, Billi JE et al. 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 1– 12. Resuscitation 2010; 81 (Suppl 1): e1– e332. doi: 10.1016/ j.resuscitation.2010.08.002.

38. Nolan JP, Soar J, Zideman DA et al. European Resuscitation Council guidelines for resuscitation 2010. Section 1– 10. Resuscitation 2010; 81(10): 1219– 1452. doi: 10.1016/ j.resuscitation.2010.08.021.

39. Mundell WC, Kennedy CC, Szostek JH et al. Simulation technology for resuscitation training: Systematic review and meta-analysis. Resuscitation 2013; 84(9): 1174– 1183. doi: 10.1016/ j.resuscitation.2013.04.016.

40. Castells MC (Ed). Anaphylaxis and hypersensitivity reactions. New York: Springer – Humana Press Inc 2011: 361.

41. Zuraw BL. Angioedema. Immunol Allergy Clin North Am 2013; 33(4): xi– xiii. doi: 10.1016/ j.iac.2013.09.002.

42. Simons FE, Ardusso LR, Dimov V et al. World Allergy Organization anaphylaxis guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013; 162(3): 193– 204. doi: 10.1159/ 000354543.

43. Cicardi M, Bork K, Caballero T et al. Hereditary Angioedema International Working Group. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67(2): 147– 157. doi: 10.1111/ j.1398-9995.2011.02751.x.

44. Maurer M, Longhurst HJ, Fabien V et al. Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc 2014; 35(5): 377– 381. doi: 10.2500/ aap.2014.35.3780.

45. Banerji A, Busse P, Shennak M et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 2017; 376(8): 717– 728. doi: 10.1056/ NEJMoa1605767.

46. Gubo G, Gavornik P, Dukát A. New perspectives in classification, diagnosis and management of angioedema. 4th Congress of the European Society for Vascular Medicine, Prague, 2018. Kazuistiky v angiologii 2018; 5(1): 33– 34.

47. Bernstein JA, Cremonesi P, Hoffmann TK et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med 2017; 10(1): 15. doi: 10.1186/ s12245-017-0141-z.

48. Gavorník P. Angiológia 2 pre všeobecných praktických lekárov. Arteriológia. 1. vyd. Bratislava: Dr. Josef Raabe 2014.

49. Gavorník P, Gašpar Ľ, Dukát A. Manažment angioedému. Odporúčania Angiologickej sekcie Slovenskej lekárskej komory (2013). Vnitř Lék 2014; 60(5– 6): 490– 498.

50. Gavorník P, Gašpar Ľ, Dukát A. Nová klasifikácia, diagnóza a manažment angioedému. Odporúčania Angiologickej sekcie Slovenskej lekárskej komory. Anestéziol Intenziv Med 2013; 2(2): 71– 76.